Log in to search using one of your social media accounts:

 

General practitioners accurately diagnose DVT with US
General practitioners can be trained in compression ultrasonography to accurately...Read more on AuntMinnie.comRelated Reading: Role of imaging modalities is changing for PE diagnosis Ultrasound elevates diagnosis of pulmonary embolism Can ultrasound for deep vein thrombosis cause a PE? Ultrasound screening catches embolism in cancer patients AAOS includes DVT US on Choosing Wisely list (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 17, 2017 Category: Radiology Source Type: news

Naturally occurring molecule may help prevent and treat atherosclerosis and gum disease
(Boston University School of Medicine) Resolvin E1, a molecule produced naturally in the body from an omega -3 fish oil, topically applied on gum tissues not only prevents and treats gum disease as previously shown (Hasturk et al 2006 and 2007), but also decreases the likelihood for advanced arterial atherosclerotic plaques to rupture and form a dangerous thrombus or blood clot. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 16, 2017 Category: International Medicine & Public Health Source Type: news

Venous thromboembolism in major trauma patients: a single-center retrospective cohort study of the epidemiology and utility of D-dimer for screening - Yumoto T, Naito H, Yamakawa Y, Iida A, Tsukahara K, Nakao A.
AIM: Venous thromboembolism (VTE) can be a life-threatening complication after major trauma. The aim of this study was to investigate the epidemiology of VTE and to assess the usefulness of D-dimer for screening for VTE in major trauma cases among the Japa... (Source: SafetyLit)
Source: SafetyLit - November 13, 2017 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Response after single treatment with canakinumab predicts which patients will benefit most
(Brigham and Women's Hospital) A pre-specified analysis on CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) that identifies a simple, clinical method to define patient groups most likely to benefit from long-term canakinumab treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 13, 2017 Category: International Medicine & Public Health Source Type: news

Initiatives to Reduce Catheter-Related Complications Drive U.S. Vascular Access Devices and Accessories Market
Conclusion The U.S. market for vascular access devices will continue to grow through 2024, and will be spurred by new catheter technology and accessories intended to improve patient outcomes. Going forward, healthcare workers will follow appropriate usage guidelines in greater numbers, and purchasers will exercise preference towards catheters and other products that reduce complications. The specialized catheter securement market is poised to benefit considerably from these trends. References U.S. Vascular Access Device Market – 2018. iData Research. Chopra V, Flanders S, Saint S, Woller S, O'Grady N, Safdar N et al...
Source: MDDI - November 7, 2017 Category: Medical Devices Tags: Tubing Medical Device Business Source Type: news

Pharmacologic VTE prophylaxis may not reduce risk of VTE following spine surgery
Data from a study published online in The Spine Journal suggest that pharmacologic prophylaxis may not significantly reduce venous thromboembolism (VTE) following spine surgery, but may increase other risks.  (Source: Orthogate - Latest News)
Source: Orthogate - Latest News - November 5, 2017 Category: Orthopaedics Tags: Featured Editors Choice News Source Type: news

TCT 2017: Medtronic touts results from 6-month Evolut Pro study
Medtronic (NYSE:MDT) today released six-month data from a study of its Evolut Pro transcatheter aortic valve replacement platform, touting low rates of paravalvular leaks and low rates of all-cause mortality and disabling stroke. Data came from 60 patients in the trial who received the Evolut Pro valve, and follow previously released 30-day outcomes. Results at six-months indicated trace or no paravalvular leaks in 88% of patients, with low rates of all-cause mortality and disabling stroke. No instances of coronary obstruction or valve thrombosis were reported and the permanent pacemaker implantation rate was 11....
Source: Mass Device - November 2, 2017 Category: Medical Devices Authors: Fink Densford Tags: Catheters Clinical Trials Replacement Heart Valves Medtronic Source Type: news

ABSORB: Bioresorbable Vascular Scaffold Fades Away in Trials ABSORB: Bioresorbable Vascular Scaffold Fades Away in Trials
Three years on, device thrombosis rates were significantly higher with the Absorb bioresorbable vascular scaffold than with a drug-eluting metal stent, new data show.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 2, 2017 Category: Consumer Health News Tags: Cardiology News Source Type: news

Here ’s how Amaranth Medical plans to get ahead with its bioresorbable scaffold tech
There are two ways to make a bioresorbable, drug-eluting scaffold, according to Amaranth Medical CEO Kamal Ramzipoor. “The Amaranth way, or the conventional way, which our competition is using,” he told Drug Delivery Business News. “What we’ve seen throughout the years is the conventional method has some very significant limitations. And that’s what has manifested itself into, unfortunately, what’s going on.” Bioresorbable scaffolds have been plagued by safety concerns, highlighted recently by Abbott‘s (NYSE:ABT) Absorb device, which it pull...
Source: Mass Device - November 2, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Cardiovascular Clinical Trials Drug-Device Combinations Drug-Eluting Stents Implants Pharmaceuticals Abbott Amaranth Medical Source Type: news

Arterial Thrombus Stability: Does It Matter? Arterial Thrombus Stability: Does It Matter?
This review summarizes evidence for the relevance of arterial thrombus stability in determination of clinical outcome, highlighting the need for tests and imaging techniques for thrombus assessment.Journal of the American College of Cardiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 1, 2017 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

FDA Clears Rivaroxaban (Xarelto) for Extended VTE Prevention FDA Clears Rivaroxaban (Xarelto) for Extended VTE Prevention
The agency approves rivaroxaban 10 mg once daily for reducing the ongoing risk for recurrent venous thromboembolism following at least 6 months of initial anticoagulation therapy.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 30, 2017 Category: Consumer Health News Tags: Cardiology News Alert Source Type: news

FDA Approves New 10 mg Dosing for XARELTO ® (rivaroxaban) to Reduce the Continued Risk of Venous Thromboembolism (VTE)
(Source: Johnson and Johnson)
Source: Johnson and Johnson - October 30, 2017 Category: Pharmaceuticals Source Type: news

Complex Bifurcation Stenting Approach Bests Provisional Stenting
(MedPage Today) -- Double kissing crush technique cut target lesion failure and thrombosis (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - October 30, 2017 Category: Cardiology Source Type: news

FDA Approves New 10 mg Dosing for XARELTO(R) (rivaroxaban) to Reduce the Continued Risk of Venous Thromboembolism (VTE)
XARELTO® is the only Factor Xa inhibitor to demonstrate superior efficacy in reducing the continued risk of recurrent VTE after initial treatment and with major bleeding rates similar to aspirin Phase 3 EINSTEIN CHOICE study shows XARELTO® 10 mg... Biopharmaceuticals, FDA Janssen Pharmaceuticals, XARELTO, rivaroxaban, Venous Thromboembolism (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 30, 2017 Category: Pharmaceuticals Source Type: news

Bayer receives FDA approval for Xarelto ® 10 mg once daily for the extended treatment of venous thromboembolism (for specialized target groups only)
Rivaroxaban (Xarelto ®) 10 mg once daily significantly reduces the risk of recurrent venous thromboembolism compared with aspirin 100 mg once daily following at least six months of standard anticoagulation therapy / FDA approval based on data from the EINSTEIN CHOICE study (Source: Bayer Company News)
Source: Bayer Company News - October 30, 2017 Category: Pharmaceuticals Source Type: news

FDA Approves New 10 mg Dosing for Xarelto (rivaroxaban) to Reduce the Continued Risk of Venous Thromboembolism (VTE)
TITUSVILLE, NJ, OCTOBER 30, 2017 – Janssen Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration (FDA) approved the 10 mg once-daily dose of Xarelto (rivaroxaban) for reducing the continued risk for recurrent venous... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 30, 2017 Category: Drugs & Pharmacology Source Type: news

Public awareness of atrial fibrillation is low
(Wiley) In a Research and Practice in Thrombosis and Haemostasis study that surveyed the general public in 10 countries, only 48% of people were aware of atrial fibrillation (AF), which is lower than the awareness of other common diseases. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 27, 2017 Category: International Medicine & Public Health Source Type: news

Medinol wins CE Mark for EluNir drug-eluting coronary stent system
Medinol said today that it won CE Mark clearance for its EluNir drug-eluting stent – a device designed with a low metal footprint and a elastomeric coating. In one 958-patient clinical study, the coronary stent had a 12-month target lesion failure rate of 5.4% and a 0% rate of late stent thrombosis, proving non-inferior to the Resolute zotarolimus-eluting stent. Get the full story at our sister site, Drug Delivery Business News. The post Medinol wins CE Mark for EluNir drug-eluting coronary stent system appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - October 26, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Pharmaceuticals Regulatory/Compliance Vascular Wall Street Beat Medinol Ltd Source Type: news

New way to treat cholesterol may be on the horizon
(Houston Methodist) A breakthrough discovery by scientists at Houston Methodist Research Institute could change the way we treat cholesterol. Researchers found new evidence that challenges a 40-year notion of how fast we eliminate it from our bodies. This accidental discovery reveals a new pathway in the cholesterol-elimination chain that will be key to developing new drugs to lower cholesterol. Their findings are described in the American Heart Association's Arteriosclerosis, Thrombosis, and Vascular Biology journal. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 26, 2017 Category: International Medicine & Public Health Source Type: news

Acute kidney failure with VTE proves difficult to treat
(American College of Chest Physicians) Researchers from the Walter Reed National Military Medical Center conducted a prospective, observational study to assess the impact that weight and renal function have on venous thromboembolism (VTE) rates among in-patients receiving prophylaxis with low-molecular-weight or unfractionated heparin. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 23, 2017 Category: International Medicine & Public Health Source Type: news

Apixaban -- metabolism, pharmacologic properties and drug interactions
(Bentham Science Publishers) New oral anticoagulants (NOACs) represent direct-acting drugs functioning selectively for one specific clotting factor. Their clinical indications are the prophylaxis and treatment of deep venous thrombosis and pulmonary embolism, the prevention of atherothrombotic episodes of individuals with acute coronary syndromes and atrial fibrillation (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 20, 2017 Category: International Medicine & Public Health Source Type: news

Newer Blood Thinners May Not Bring Higher Bleeding Risk
Risk is similar to warfarin, study reports Source: HealthDay Related MedlinePlus Pages: Atrial Fibrillation, Blood Thinners, Deep Vein Thrombosis (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - October 18, 2017 Category: Consumer Health News Source Type: news

In VTE, Bleeding Risk No Higher with Direct Oral Anticoagulants Than Warfarin (FREE)
By Amy Orciari Herman Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM Direct oral anticoagulants do not pose higher risk for major bleeding than warfarin in patients with venous thromboembolism (VTE), according … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - October 18, 2017 Category: Primary Care Source Type: news

European task force: Docs should favor drug-eluting stents over bioresorbable scaffolds
Physicians should not use bioresorbable scaffolds in place of current-generation drug-eluting stents, according to a report from the European Society of Cardiology and European Association of Percutaneous Cardiovascular Inventions. The ECS/EAPCI report says that as long as concerns remain about the increased risk of myocardial infarction and scaffold thrombosis linked with bioresorbable scaffolds, physicians should favor using drug-eluting stents. Get the full story at our sister site, Drug Delivery Business News. The post European task force: Docs should favor drug-eluting stents over bioresorbable scaffolds appeared firs...
Source: Mass Device - October 12, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Cardiovascular Clinical Trials Drug-Device Combinations Drug-Eluting Stents Pharmaceuticals Research & Development Wall Street Beat Abbott Biotronik Boston Scientific Elixir Medical Corp. Reva Medical Inc. Source Type: news

National Trauma Institute Appoints Priority Ambulance ’s Dennis Rowe to Board of Directors
The National Trauma Institute (NTI) recently elected five new members to its Board of Directors, including Priority Ambulance Director of New Business Integration Dennis Rowe who will serve as the liaison member from the National Association of EMTs (NAEMT). NTI is a national nonprofit organization that advocates for increased federal funding for trauma research and research infrastructure to reduce death and disability. Rowe currently serves as president of NAEMT. He began involvement with NAEMT in 1976 rising soon to board and leadership positions. NAEMT is the recognized leader in advancing the profession of emergency a...
Source: JEMS Administration and Leadership - October 9, 2017 Category: Emergency Medicine Authors: Priority Ambulance Tags: Administration and Leadership Industry News Source Type: news

National Trauma Institute Appoints Priority Ambulance ’s Dennis Rowe to Board of Directors
The National Trauma Institute (NTI) recently elected five new members to its Board of Directors, including Priority Ambulance Director of New Business Integration Dennis Rowe who will serve as the liaison member from the National Association of EMTs (NAEMT). NTI is a national nonprofit organization that advocates for increased federal funding for trauma research and research infrastructure to reduce death and disability. Rowe currently serves as president of NAEMT. He began involvement with NAEMT in 1976 rising soon to board and leadership positions. NAEMT is the recognized leader in advancing the profession of emergency a...
Source: JEMS: Journal of Emergency Medical Services News - October 9, 2017 Category: Emergency Medicine Authors: Priority Ambulance Tags: Administration and Leadership Industry News Source Type: news

NICE updates guidance on reducing risk of VTE on admission
The National Institute for Health and Care Excellence has published its draft guideline on reducing the risk of venous thromboembolism in patients admitted to hospital or mental health units. (Source: Nursing Times)
Source: Nursing Times - October 9, 2017 Category: Nursing Source Type: news

Nigeria: Lettuce 'Cure' for Depression, Stroke, Thromboembolism
[Guardian] Can eating meals rich in lettuce provide relief from anxiety, depression, chronic pain, sleeplessness, indigestion, lack of appetite, blood clots, heart attack, stroke and thromboembolism? CHUKWUMA MUANYA (Assistant Editor) writes. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - October 6, 2017 Category: African Health Source Type: news

Editor's highlight: pulmonary vascular thrombosis in rats exposed to inhaled sulfur mustard - McGraw MD, Osborne CM, Mastej EJ, Di Paola JA, Anderson DR, Holmes WW, Paradiso DC, Garlick RB, Hendry-Hofer TB, Rancourt RC, Smith RW, Burns C, Roe GB, Rioux JS, White CW, Veress LA.
Sulfur mustard (SM) is a chemical warfare agent. When inhaled, SM causes significant injury to the respiratory tract. Although the mechanism involved in acute airway injury after SM inhalation has been well described previously, the mechanism of SM's contr... (Source: SafetyLit)
Source: SafetyLit - October 4, 2017 Category: International Medicine & Public Health Tags: Burns, Electricity, Explosions, Fire, Scalds Source Type: news

Replacing Warfarin With a Novel Oral Anticoagulant Replacing Warfarin With a Novel Oral Anticoagulant
A good percentage of patients with atrial fibrillation may be ineligible for warfarin due to increased risk of major bleeding or recurrent systemic thromboembolism. Are DOACs a viable alternative?Journal of Cardiovascular Electrophysiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 2, 2017 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Angiodynamics shares tumble on Q1 sales, EPS miss
Shares in AngioDynamics (NSDQ:ANGO) have dropped over 10% today after the medical device maker missed expectations on Wall Street with its 1st quarter results. The Albany. N.Y.-based company posted losses of $35,000, or 0¢ per share, on sales of $85.4 million for the 3 months ended August 31, seeing the bottom-line swing 102.7% into the red while sales shrunk 3.1% compared to the same period the previous year. After adjusting to exclude 1-time items, earnings per share were 12¢, behind the 16¢ consensus on Wall Street, where analysts were expecting to see sales of $86.1 million for the quarter. “T...
Source: Mass Device - September 28, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup AngioDynamics Source Type: news

Cancer Risk Up for RA Patients With Venous Thromboembolism
Risk of cancer increased during the first year after VTE and in longer follow - up period (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 27, 2017 Category: Cancer & Oncology Tags: Family Medicine, Geriatrics, Gynecology, Internal Medicine, Critical Care, Emergency Medicine, Nursing, Oncology, Orthopedics, Pathology, Pulmonology, Radiology, Rheumatology, Anesthesiology & Pain, Journal, Source Type: news

Your NEJM Group Today: Thrombophilia Testing Review Article / Self-Grooming Disorders / California Pulmonary & Sleep Opportunities (FREE)
By the Editors Here's what we chose for you from NEJM Group today:NEJM Clinical Practice Center: Review Article: Most patients with venous thromboembolism do not … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 26, 2017 Category: Primary Care Source Type: news

What Causes Microcephaly?
Patient Presentation A 5-month-old male came to clinic for his health supervision visit and followup from his neonatal intensive care stay. He was born prematurely at 28 weeks gestation and his stay was complicated by a right sided Grade III intraventricular hemorrhage, a left-sided Grade IV intraventricular hemorrhage, neonatal seizures, respiratory distress and bronchopulmonary dysplasia, retinopathy of prematurity, acute kidney injury that had resolved, possible necrotizing enterocolitis incidents x 2, and herpes simplex encephalitis. He was on home oxygen, a nasogastric feeding tube because of aspiration risk and mult...
Source: PediatricEducation.org - September 25, 2017 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

7 medtech stories we missed this week: Sept. 22, 2017
[Image from unsplash.com]From the FDA’s clearance of Covalon’s film-drape to Bioventus launching its study, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. FDA clears Covalon’s MediClear OTC surgical film-drape Covalon announced in a Sept. 21 press release that the FDA has cleared its MediClear PreOp to market in U.S. hospitals, clinic and directly to patients without a prescription. The MediClear PreOp is a breathable, transparent, self-adhesive, silicone barrier film-drape that can conform to a patient’s skin at a planned incision or insertion si...
Source: Mass Device - September 22, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: Business/Financial News Diagnostics Food & Drug Administration (FDA) Laboratory Instruments/Laboratory Supplies mHealth (Mobile Health) Research & Development Vascular Bioventus LLC Contego Medical Covalon Technologies Getinge Guerbe Source Type: news

World Thrombosis Day Webinar: Advances in Reducing the Disease Burden of Thrombosis
October 12, 2017 11:00am ET. (Source: HSR Information Central)
Source: HSR Information Central - September 22, 2017 Category: International Medicine & Public Health Source Type: news

ManaMed Inc. Introduces PlasmaFlow, The World's First FDA-Approved Digital and Tubeless Deep Vein Thrombosis Prevention Device
PlasmaFlow Is Deep Vein Thrombosis (DVT) Prevention Made Simple SANTA ANA, Calif., Sept. 21, 2017 -- (Healthcare Sales & Marketing Network) -- The company's historical first FDA-approved portable and tubeless DVT prevention device is now available to m... Devices, Product Launch ManaMed, PlasmaFlow, Deep Vein Thrombosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 21, 2017 Category: Pharmaceuticals Source Type: news

Cardinal Health inks distro deal with Avadim Tech
Life science company Avadim Technologies said yesterday it inked a deal withCardinal Health (NYSE:CAH) to distribute Avadim’s Theraworx topical bionome therapies designed to prevent catheter-associated urinary tract infections and complications. The companies said that the Theraworx topical solution will compliment Cardinal Health’s Dover urological portfolio. “We are honored to partner with one of the most influential leaders in healthcare across the globe. Cardinal Health’s commitment to improving healthcare for more people, in more ways, and in more places than ever before is directly aligne...
Source: Mass Device - September 20, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Distribution Urology Cardinal Health Source Type: news

MassDevice.com +5 | The top 5 medtech stories for September 20, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. The 10 largest medical device companies in the world Mergers & acquisitions continue to change the medical device landscape, as reflected in Medical Design & Outsourcing’s new Big 100 list. We pulled financial reg...
Source: Mass Device - September 20, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Reva Medical ’s Fantom bioresorbable, drug-eluting vascular scaffold succeeds at 6 months
As some companies have worked to improve drug-eluting stents by making them bioresorbable, some voices in the coronary intervention space have expressed concern over the rates of late stent thrombosis and repeat percutaneous coronary intervention seen with the devices. In a study published in the September issue of JACC: Cardiovascular Intervention, Reva Medical‘s (ASX:RVA) Fantom coronary bioresorbable vascular scaffold succeeded after six months. The device was designed to address challenges like strut size and expansion capacity, the researchers wrote. Get the full story at our sister site, Drug Delivery...
Source: Mass Device - September 20, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Cardiovascular Clinical Trials Drug-Device Combinations Drug-Eluting Stents Pharmaceuticals Wall Street Beat Abbott Reva Medical Inc. Source Type: news

DVT (Deep Vein Thrombosis) and Pulmonary Embolism (PE) Quiz
Title: DVT (Deep Vein Thrombosis) and Pulmonary Embolism (PE) QuizCategory: MedicineNet QuizCreated: 7/31/2014 12:00:00 AMLast Editorial Review: 9/20/2017 1:12:43 PM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - September 20, 2017 Category: Cardiology Source Type: news

Studies support anti-stroke PFO closure devices from Abbott, Gore
Sykes and Clark; licensee BioMed Central Ltd. A trio of studies published this week in the New England Journal of Medicine showed that devices from Abbott (NYSE:ABT) and W.L. Gore & Assoc. designed to close a heart defect lowered the risk of a recurring episode in certain cryptogenic stroke patients. Long-term results from the 980-patient Respect trial of the Amplatzer device Abbott acquired along with St. Jude Medical this year, along with data from the Reduce study of Gore’s Helex and Cardioform and the French Close study of PFO closure devices with CE Mark approval, showed that they reduced the risk of re...
Source: Mass Device - September 15, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Cardiovascular Clinical Trials Surgical Abbott Structural heart W.L. Gore & Associates Source Type: news

New European Guidelines for Cerebral Venous Thrombosis New European Guidelines for Cerebral Venous Thrombosis
The guidelines, which cover both the diagnosis and treatment of cerebral venous thrombosis, are based purely on scientific evidence and make several new recommendations, rated as'clear'or'weak. 'Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 15, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Bayer receives positive CHMP opinion for rivaroxaban 10 mg once daily for the extended prevention of venous thromboembolism (for specialized target groups only)
Rivaroxaban 10 mg once daily significantly reduces the risk of recurrent venous thromboembolism compared with aspirin 100 mg once daily after at least six months of standard anticoagulation therapy / Positive CHMP Opinion is based on data from the Phase III EINSTEIN CHOICE study / Final European Commission decision expected by November 2017 (Source: Bayer Company News)
Source: Bayer Company News - September 15, 2017 Category: Pharmaceuticals Source Type: news

Device used to close small hole in heart may protect against recurrent stroke
A device used to close a small hole in the heart may benefit certain stroke patients by providing an extra layer of protection for those facing years of ongoing stroke risk, according to the results of a large clinical trial led by UCLA researchers.“It is a major new treatment option for some people,” said Dr. Jeffrey Saver, director of theUCLA Comprehensive Stroke Center and lead author of the study. However, he added, “Using the device is going to have to be a considered clinical decision between the doctor and the patient about who’s the right person to get it.”Thefindings appear in the Sep...
Source: UCLA Newsroom: Health Sciences - September 14, 2017 Category: Universities & Medical Training Source Type: news

Tall people have greater risk of thrombosis
Researchers find strong correlation between height and risk of venous thromboembolism in both women and men Related items fromOnMedica Obese women on the pill more likely to have rare stroke Diagnosis and management of deep vein thrombosis Self-managing anticoagulants may cut risks after surgery Rising use of antithrombotics linked to subdural haematoma (Source: OnMedica Latest News)
Source: OnMedica Latest News - September 12, 2017 Category: UK Health Source Type: news

Taller patients at ‘greater risk’ of venous thromboembolism
The risk of a patient developing venous thromboembolism (VTE) increases with their height, with taller people more likely to experience it, according to Swedish researchers. (Source: Nursing Times)
Source: Nursing Times - September 11, 2017 Category: Nursing Source Type: news

MAUDE: Post-TAVR Leaflet Thrombosis Not Benign MAUDE: Post-TAVR Leaflet Thrombosis Not Benign
While post-TAVR leaflet thrombosis can cause valve dysfunction or even cardiogenic shock and death, the question remains whether there's justification for routine anticoagulation given its inherent risks.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 8, 2017 Category: Consumer Health News Tags: Cardiology News Source Type: news

Recalled in US: Three Lots of Alteplase (Activase), Vial Leakage Hazard Recalled in US: Three Lots of Alteplase (Activase), Vial Leakage Hazard
Genentech says the thrombolytic agent in 100 mg vials was copackaged with sterile water for injection; the water vials may be"cracked or chipped" and no longer sterile.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 7, 2017 Category: Consumer Health News Tags: Cardiology News Alert Source Type: news

People over 6ft 2in at higher risk of heart attacks
The Lund University, Sweden, study, which compared siblings to rule out genetic factors, found a direct correlation between height and risk of venous thromboembolism. (Source: the Mail online | Health)
Source: the Mail online | Health - September 6, 2017 Category: Consumer Health News Source Type: news